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ARTICLE
Missing self triggers NK cell-mediated chronic
vascular rejection of solid organ transplants
Alice Koenig1,2,3, Chien-Chia Chen 1, Antoine Marçais1, Thomas Barba1,2,3, Virginie Mathias1,4,
Antoine Sicard1,2,3, Maud Rabeyrin5, Maud Racapé6, Jean-Paul Duong-Van-Huyen6, Patrick Bruneval6,
Alexandre Loupy6, Sébastien Dussurgey7, Stéphanie Ducreux1,4, Vannary Meas-Yedid8,
Jean-Christophe Olivo-Marin8, Héléna Paidassi1, Romain Guillemain9, Jean-Luc Taupin10,11,12,
Jasper Callemeyn13,14, Emmanuel Morelon1,2,3, Antonino Nicoletti12,15, Béatrice Charreau 16, Valérie Dubois1,4,
Maarten Naesens13,14, Thierry Walzer1,17, Thierry Defrance1,17 & Olivier Thaunat1,2,3*
Current doctrine is that microvascular inﬂammation (MVI) triggered by a transplant -reci-
pient antibody response against alloantigens (antibody-mediated rejection) is the main cause
of graft failure. Here, we show that histological lesions are not mediated by antibodies in
approximately half the participants in a cohort of 129 renal recipients with MVI on graft
biopsy. Genetic analysis of these patients shows a higher prevalence of mismatches between
donor HLA I and recipient inhibitory killer cell immunoglobulin-like receptors (KIRs). Human
in vitro models and transplantation of β2-microglobulin-deﬁcient hearts into wild-type mice
demonstrates that the inability of graft endothelial cells to provide HLA I-mediated inhibitory
signals to recipient circulating NK cells triggers their activation, which in turn promotes
endothelial damage. Missing self-induced NK cell activation is mTORC1-dependent and the
mTOR inhibitor rapamycin can prevent the development of this type of chronic vascular
rejection.
https://doi.org/10.1038/s41467-019-13113-5 OPEN
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The best (and often the only) therapeutic option for patientswith end-stage vital organ failure is organ transplantation.However, the antigenic determinants that differ between
the donor and the recipient (alloantigens), in particular the highly
polymorphic molecules from the major histocompatibility com-
plex (MHC, i.e. human leucocyte antigen (HLA) in humans), are
recognised by the adaptive immune system of the recipient1,
which can lead to the failure of the transplanted organ, a process
named “rejection”.
Until the end of the 1970s, the occurrence of acute cellular
rejection episodes, i.e. the destruction of the graft by the recipient’s
cytotoxic T cells, was the main obstacle to the success of trans-
plantation. Introduction of calcineurin inhibitors in the early 1980s
led to a dramatic reduction of the incidence of acute cellular
rejection, and doubled the percentage of functional renal grafts at 1-
year post-transplantation2. However, this progress in the control of
T cell alloimmune response barely affected graft half-life3, leading to
the emergence of the “humoral theory” of chronic rejection4.
First identiﬁed in renal transplantation in the 2000s5–8,
antibody-mediated rejection (AMR) has since been recognised as
the main cause of failure in most organ transplantations9–12.
Graft endothelium is the biological interface between donor
alloantigens and host antibodies, which are retained in the reci-
pient’s circulation due to their size13. Binding of circulating anti-
HLA donor-speciﬁc antibodies (DSAs) to directly accessible targets
expressed by endothelial cells (ECs) of graft microvasculature can
activate the classical complement pathway, thereby accelerating the
rejection process14,15. This is, however, not mandatory for the
development of chronic AMR16,17. Engagement of the surface Fc
receptors of innate immune effectors by anti-HLA DSA bound to
graft microvasculature is sufﬁcient to trigger the release of lytic
enzymes that mediate the activation and/or damage of the endo-
thelial cell layer. For this reason, the presence of microvascular
inﬂammation (MVI) in graft biopsy is widely considered as the
histological hallmark of AMR18,19.
Our present translational study challenges this idea. Analysing
a cohort of 129 renal transplant patients we ﬁnd that MVI in graft
biopsy is not mediated by antibodies in almost half of the cases.
Instead, genetic analyses suggest that microvascular lesions are a
result of direct activation of recipient NK cells by graft ECs. We
ﬁnd that graft ECs are unable to deliver inhibitory signals to
recipient NK cells because of different (mismatched) HLA class I
molecules (HLA I). This mimics the “missing self” for NK cells,
and we show that this is sufﬁcient to provoke EC damage in vitro
and in vivo. Importantly, we ﬁnd that the mTORC1 pathway in
NK cells is mandatory for this effect. Preclinical studies using
experimental mouse models of transplantation conﬁrm the efﬁ-
ciency of the mTORC1 inhibitor rapamycin to prevent the
development of NK cell-mediated histological lesions.
Results
Antibodies are not the only trigger for graft MVI. In kidney
transplantation, MVI is deﬁned as the presence of innate immune
effectors in the lumen of peritubular capillaries (peritubular
capillaritis, ptc) and/or glomeruli (glomerulitis, g)20. We retro-
spectively reviewed all kidney graft biopsies performed at our
University Hospital between September 2004 and September 2012
(n= 2024 in 938 patients) and identiﬁed 129 renal recipients with
typical graft MVI (g+ ptc ≥ 2). The clinical characteristics of these
patients are presented in Supplementary Table 1.
Interestingly, only 54% (70/129) of these patients had
detectable circulating anti-donor HLA antibodies (i.e. “typical
AMR”; Fig. 1a).
Previous studies have shown that bona ﬁde AMRs can be
triggered by non-HLA antibodies directed against either minor
histocompatibility alloantigens or autoantigens1,21–25. Screening
of patients’ sera for anti-angiotensin II type 1-receptor (AT1R)
and anti-MHC class I polypeptide-related sequence (MIC), two
types of non-HLA antibodies the pathogenicity of which has been
demonstrated26,27, showed that neither the titre nor the
proportion of positive patients were increased in the MVI
+anti-HLA DSA− group (Supplementary Fig. 1A). Although it is
impossible to test for all non-HLA speciﬁcities, previous studies
have demonstrated that only antibodies able to bind to the surface
of graft ECs can have a deleterious impact13. Flow cytometric
cross-match with activated HLA-matched ECs28 was therefore
used to screen patients’ sera for non-HLA anti-endothelial cell
antibodies (Supplementary Fig. 1B, C). These experiments
identiﬁed six patients (6/129, 4.6%) for whom non-HLA anti-
endothelial cell antibodies could account for graft MVI
(Supplementary Fig. 1D, E, Fig. 1a). Based on these results, we
concluded that in almost half of the cases (53/129, 41.1%; group
MVI+DSA−), graft MVI was not caused by host humoral
response.
Antibody-independent MVI affects graft survival. The binding
of large amounts of antibodies to graft endothelium triggers the
classical complement pathway29 responsible for acute tissue
injuries, which dramatically curtail graft survival14,15. However,
even in the absence of complement activation, DSA can still
recruit innate immune effectors, and this MVI has a detrimental
impact on graft survival16.
In our cohort, we observed that of the 70 renal recipients with
typical AMR (i.e. circulating anti-HLA DSA and MVI on graft
biopsy), the 40 patients whose DSA were able to activate the
complement cascade in vitro (group MVI+DSA+C3d+, Fig. 1a),
had the highest score for C4d deposition in graft biopsy (Fig. 1b)
and the worst graft survival (Fig. 1c).
Interestingly, the 53 patients with antibody-independent MVI
(group MVI+DSA−) had the same graft survival as the 30
patients with AMR, owing to non-complement activating DSA
(group MVI+DSA+C3d−). Graft survivals of these two groups
were signiﬁcantly better than that of MVI+DSA+C3d+ patients,
but signiﬁcantly worse than that of a matched control cohort
without MVI or DSA (group MVI−DSA−) as shown in Fig. 1c.
We conclude that regardless of whether it is antibody-
dependent or -independent, MVI has the same detrimental
impact on graft survival.
NK cells in antibody-dependent and antibody-independent
MVI. The nature and number of immune cells inﬁltrating the renal
allograft of patients with available biopsy material from MVI+
DSA+C3d+ (n= 17), MVI+DSA+C3d− (n= 14), and MVI+
DSA− (n= 32) groups were compared using the computer-assisted
analysis of graft inﬂammation (CAGI) method30. This approach
allows a precise quantiﬁcation of the innate and adaptive immune
cell subset density in the microcirculation and the tubulointerstitial
compartment of a renal allograft (Supplementary Fig. 2A, B).
Quadratic discriminant analysis efﬁciently separated MVI+DSA+
C3d+ and MVI+DSA− patients, but a major overlap was observed
between MVI+DSA+C3d− and MVI+DSA− (Fig. 1d), which
suggests that a common pathophysiological process is taking place
in the renal allografts of these two groups.
Antibodies that are unable to activate the complement cascade
can still recruit FcΥ receptor-expressing innate immune effectors,
which are responsible for antibody-dependent cell-mediated
cytotoxicity (ADCC), thus leading to chronic/subclinical AMR6.
Seminal experimental17,31 and clinical32 studies have demonstrated
that among innate immune effectors, NK cells are crucial for the
development of complement-independent AMR lesions. In line
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with this data, NK cells were present in the graft microcirculation of
MVI+DSA+C3d− patients (Fig. 1e). Interestingly, NK cell
inﬁltration was similar in MVI+DSA− patients, whose MVI was
not triggered by antibody deposition on the graft endothelium
(Supplementary Fig. 2B). We therefore concluded that in chronic
vascular rejection, a ﬁnal common pathway involving NK cells
could be either triggered classically by the humoral arm of the
adaptive immune system of the recipients or induced by a direct
antibody-independent activation of innate effectors.
Missing self increases the risk of antibody-independent MVI.
In steady state, the interaction of inhibitory KIRs with self-HLA I
molecules of surrounding healthy cells provides a negative signal
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to NK cells (a graphical summary of this information is presented
in Supplementary Fig. 3A)33,34. On the contrary, the down-
regulated expression of HLA I molecules associated with tumoral
transformation or viral infection triggers NK cell activation,
which results in the destruction of the target cell, a process named
response to “missing self”. Of note, because the HLA locus is
located on chromosome region 6p21, whereas the KIR locus is on
19q13.4, HLA and KIR are inherited independently. NK cells
need to undergo a process of education, in which auto-reactive
NK cells (owing to the lack of expression of HLA I ligands for
their inhibitory KIRs) are rendered anergic (Fig. 2a).
We reasoned that although graft ECs express a normal level of
HLA I molecules (Fig. 2b, Supplementary Fig. 4A), their
allogeneic nature could theoretically induce a situation in which
donor ECs express an HLA I allotype that is unable to interact
with an educating inhibitory KIR expressed by the recipient’s NK
cells (i.e. “pseudo-missing self”; Fig. 2a). To test whether this
hypothesis could explain antibody-independent graft MVI, we
integrated, for each donor/recipient pair, the genetic analyses of
recipient inhibitory KIRs and recipient HLA I (Supplementary
Table 2) in order to identify educating inhibitory KIRs. Recipient
data were then combined with the donor HLA I genotype
(Supplementary Table 2) to identify situations of missing self. In
line with our hypothesis, recipients with antibody-independent
MVI had statistically more genetically predicted missing self (MS)
than matched controls (Fig. 2c).
Of note, ~1/3 (15/43; 34.9%) of MVI+DSA− patients had no
genetically predicted missing self, indicating that other molecular
mechanisms can induce antibody-independent MVI (Fig. 2c). NK
cell activation is governed by the integration of the signals
provided by inhibitory and activating KIRs35. It is therefore
tempting to speculate that in some patients, the activation of
recipients’ NK cells by graft endothelium was triggered by
signalling through activating KIRs instead of (or in addition to) a
lack of signalling through inhibitory KIRs. We were, however,
unable to conﬁrm this hypothesis, because the number and
distribution of activating KIR genes were similar between MVI
−DSA− and MVI+DSA− patients (Supplementary Table 2), and
increasing the expression of KIR-activating ligands on ECs was
neither necessary nor sufﬁcient to trigger NK cell activation and
promote EC damage (Supplementary Figs. 5A and 6A). These
results, however, do not rule out the role of activating receptors in
the triggering of NK cell-mediated rejection. Beyond activating
KIRs, many other types of activating receptors exist on NK cells
(including, NKG2D, NKG2C, NKp46, NKp3, etc.).
Effect of priming and heterogeneity of the NK cell population.
Genetic analyses of the donor/recipient pairs also revealed that
~1/3 (21/55; 38.2%) of MVI−DSA− recipients had genetically
predicted missing self, suggesting that this condition alone is not
sufﬁcient to trigger graft MVI (Fig. 2c).
In contrast to long-held belief, NK cells are not naturally active
killers. Recent experimental evidence has demonstrated that
educated NK cells need to undergo priming in order to acquire
their full effector functions36–38. In clinical transplantation, two
frequent situations can promote the priming of recipient’s NK
cells: ischaemia/reperfusion injuries and viral infections. Cold
ischaemia time was longer in MVI+DSA− than in MVI−DSA−
patients (Fig. 3a) and the incidence of viral infections, in
particular cytomegalovirus infection, was higher in MVI+DSA−
patients (Fig. 3b). These data suggest that the absence of graft
MVI in some patients with genetically predicted missing self can
be explained by the absence of sufﬁcient priming of NK cells.
Another possible explanation for the absence of graft MVI in
patients with genetically predicted missing self could be the inter-
individual heterogeneity of the NK cell population. Because of the
retrospective nature of our study and the lack of frozen peripheral
blood mononuclear cells (PBMC), we were unable to test this
hypothesis directly in the cohort. Instead, we performed a ﬂow
cytometry phenotypic analysis of the circulating NK cells of six
healthy volunteers with identical inhibitory KIR genotypes
(Supplementary Fig. 3B). The absolute count of NK cells among
circulating lymphocytes showed huge inter-individual differences
(Fig. 3c, Supplementary Fig. 4B). Beyond these quantitative
disparities, variegated expression of KIR genes resulted in major
inter-individual qualitative differences in the repertoire of
inhibitory KIRs expressed by circulating NK cells (Fig. 3d). This
had two main consequences: a high proportion (38.5%) of
circulating NK cells did not express any inhibitory KIR
(Supplementary Fig. 3C). Furthermore, even for inhibitory KIR-
expressing NK cells, the proportion of NK cells able to speciﬁcally
detect alteration of a particular HLA I molecule differed widely
between the individuals (Fig. 3d). Therefore, it is conceivable that
for some recipients with genetically predicted missing self and
appropriate priming, the lack of MVI was due to the fact that the
NK cell population that expressed the appropriate inhibitory KIR
was too small.
The complexity of the clinical setting, in which each donor/
recipient pair was different, at best allows only correlations. To
conﬁrm the causality of missing self in the occurrence of NK-
mediated chronic vascular rejection of solid organ transplants we
turned to experimental approaches.
Allogeneic ECs trigger MS-induced NK cell activation in vitro.
To test whether endothelial missing self could trigger NK cell
activation, primary allogeneic human ECs were co-cultured with
NK cells puriﬁed from the PBMCs of healthy volunteers. After 4 h
of culture, NK cells were recovered and their inhibitory KIR
phenotype and activation status (i.e. expression of CD107a and
MIP-1β) was assessed at the single-cell level by ﬂow cytometry.
Our ﬁrst analysis focused on the 5 NK cell populations that
expressed only one inhibitory KIR (Supplementary Fig. 3B).
Fig. 1 Antibody-independent graft microvascular inﬂammation. Kidney-allograft biopsy material from 938 patients was screened for microvascular
inﬂammation (MVI) lesions. Presence of circulating anti-HLA donor-speciﬁc antibodies (anti-HLA DSA) and their ability to activate the complement
cascade was assessed in synchronous serum using solid-phase assays. Negative sera were additionally screened for anti-endothelial cell antibodies (anti-
EC Abs) by ﬂow cross-match (see Supplementary Fig. 1A). Three groups of patients were deﬁned: group MVI+DSA+C3d+ (n= 40; dashed black line),
group MVI+DSA+C3d− (n= 30; solid grey line), and MVI+DSA− (n= 53; solid red line). A fourth group (MVI−DSA−; n= 72; solid green line), devoid
of MVI lesions in graft biopsy and circulating donor-speciﬁc antibody but matched for clinical characteristics with MVI+DSA− patients, was established.
a Flow chart showing the distribution of the patients in the different groups. b C4d staining was quantiﬁed (0–3) in graft biopsy according to the Banff
classiﬁcation. Distribution of this parameter is shown for the four groups. nsp > 0.05; *p < 0.05, ****p < 0.0001; one-way ANOVA. c Renal graft survival
curves were compared in the four groups. nsp≥ 0.05, **p < 0.01, ***p < 0.001; log-rank test. d Scatter plot of the ﬁrst two canonical discriminant function
analyses for CAGI dataset of kidney graft biopsies. Entropy r2= 0.555. e Parafﬁn-embedded sections of graft biopsies of patients from MVI+DSA+C3d−
and MVI+DSA− groups were stained for endothelial cells (anti-CD34) and NK cells (anti-CD56). Representative images of MVI lesions found in the
glomeruli (upper row) and the peritubular capillaries (lower row) are shown. Scale bar: 100 μm.
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According to the HLA I genotypes of the ECs and NK cell donors,
three distinct situations were identiﬁed for each of these NK cell
populations (Fig. 2a): absence of missing self (no MS), presence of
missing self for a ligand not expressed by the NK cell donor
(uneducated missing self, uneduc MS), or missing self (MS). In
line with the clinical data presented above, the three groups of NK
cells behaved uniformly and showed no any sign of activation
after co-culture with the ECs in the absence of prior priming
(Supplementary Fig. 5A). After priming with low-dose IL2, NK
cells that could speciﬁcally detect the absence of expression of a
particular HLA I molecule (MS group) expressed signiﬁcantly
higher levels of both CD107a (Fig. 4a) and MIP-1β (Fig. 4b)
compared to NK cells that did not express the speciﬁc inhibitory
KIR (no MS) or that expressed the appropriate inhibitory KIR but
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were not educated (uneduc MS). This result validates our
hypothesis that allogeneic ECs can trigger missing self-induced
activation of educated NK cells only if they are primed.
To determine whether some molecular combinations were
more prone than others to promote missing self-induced NK cell
activation, the previous dataset was re-analysed considering each
inhibitory KIR separately. All inhibitory KIRs were equally able to
promote activation of primed and educated NK cells in the
absence of their speciﬁc HLA I molecule on the ECs, except for
KIR3DL2 (Supplementary Fig. 5B). This result ﬁts the conclusion
of recent independent reports39,40 and suggests that KIR3DL2
might not be an educating inhibitory KIR. Taking this into
account, we re-analysed the clinical data presented in Fig. 2c,
removing KIR3DL2 from the deﬁnition of genetically predicted
missing self. Although this simple change did not correct the
other limitations of this method (details discussed in the section
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Fig. 3 Inﬂuence of priming and heterogeneity of the NK cell population. a Cold ischaemia time was compared for patients from the MVI+DSA− and
MVI−DSA group. The centre line in the boxes shows the medians; the box limits indicate the 25th and 75th percentiles, the whiskers indicate the 10th and
90th percentiles. *p < 0.05; Mann–Whitney test. b The prevalence of viral (all viruses, upper row) and cytomegalovirus (CMV, lower row) infections were
compared for patients from MVI+DSA− (left column) and MVI−DSA− (right column) groups. *p < 0.05; **p < 0.01; Fisher’s exact test. c, d Phenotypic
analyses of circulating NK cells from six healthy volunteers (HV #1 to #6) with identical inhibitory KIR genotypes. c Left panel: individual values for
absolute count of circulating NK cells are plotted. Right panel: the dispersion of the size of NK and T lymphocyte populations in the circulation of the 6 HV
is shown. d Expression of the ﬁve inhibitory KIRs was assessed at the single cell level. The differences in distribution of the 23 NK cell subsets are shown for
the six healthy volunteers. Each axis of the radar plot represents a given combination of inhibitory KIR as indicated by the colour code on the left. The scale
of each axis is adjusted to optimise the display of every population of NK cells. Source data are provided as a Source Data ﬁle.
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“Impact of priming and heterogeneity of NK cell population”), it
was sufﬁcient to reduce the proportion of recipients with
genetically predicted missing self in the group without graft
MVI [proportion of recipients with genetically predicted missing
self in MVI-DSA- group with vs. without KIR3DL2: 21/55
(38.2%) vs. 15/55 (27.3%)].
A signiﬁcant proportion of NK cells (25.4%, Supplementary
Fig. 3C) express more than one inhibitory KIR on their surface.
To determine how these distinct signals contribute to cell
activation, we focused the analysis on NK cells that expressed
two inhibitory KIRs, one being responsible for missing self-
induced activation. Depending on the second inhibitory KIR of
the NK cell and the HLA I genotypes of the ECs, three situations
were identiﬁed: missing self+matched (MS+M), missing self+
uneducated missing self (MS+ uneduc MS) or missing self+
missing self (2MS). Activation status of the NK cells of these three
groups after co-culture with allogeneic ECs was compared to that
of NK cells expressing only one educating inhibitory KIR. The
level of expression of both CD107a and MIP-1β was increased in
2MS, and decreased in MS+ uneduc MS and the MS+M group
(Fig. 3c, d). These results demonstrate that the signals generated
by each educating inhibitory KIR expressed on the surface are
integrated by NK cells and modulate missing self-induced
activation.
MS-induced NK cell activation damage allogeneic ECs. Having
demonstrated that allogeneic ECs could trigger missing self-
induced NK cell activation, we sought to determine its impact on
ECs. To this end, the integrity of adherent ECs was monitored by
real-time impedance measurement in the co-culture model
described above.
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In a ﬁrst set of experiments (model #1, presented in Fig. 5a), we
compared the survival of the same primary allogeneic ECs
exposed to NK cells from two distinct donors: one with missing
self and the other without (negative control). The experiment,
reproduced with six different pairs, demonstrated that endothelial
cell survival was consistently reduced when co-cultured with NK
cells expressing one inhibitory KIR unable to interact with the
appropriate HLA I molecules on ECs (Fig. 5b).
To rule out the possibility that the differences observed in the
ﬁrst model were inﬂuenced by inter-individual heterogeneity of
NK cell populations between donors, we developed a second
model (model #2, presented in Fig. 5a), in which the allogeneic
ECs were co-cultured with NK cells from the same matched
donor with anti-KIR3DL1 blocking mAb or an isotype control
mAb. In line with previous results, co-cultures with anti-
KIR3DL1 blocking mAb induced an “artiﬁcial” missing self,
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Fig. 5 Missing self-induced NK cell activation is harmful for endothelial cells. a Schematic representation of the two experimental models. Puriﬁed NK cells
from healthy volunteers were co-cultured with adherent primary allogeneic human endothelial cells, the viability of which was assessed by real-time
impedance measurement. Real-time impedance data of the experimental co-culture were normalised over control. b Model #1: The same primary human
endothelial cells were co-cultured with NK cells puriﬁed from two distinct donors: the ﬁrst without missing self (control co-culture) and the second with
missing self (experimental co-culture). Individual impedance proﬁles (mean ± standard error; upper panel) and the area under the curves (lower panel)
from six independent experiments are shown. cModel #2: The same primary human endothelial cells were co-cultured with NK cells puriﬁed from a donor
without missing self, in the presence of a blocking anti-inhibitory KIR mAb (experimental co-culture) or an isotype control mAb (control co-culture).
Individual impedance proﬁles (mean ± standard error; upper panel) and area under the curves (lower panel) from six independent experiments are shown.
*p < 0.05; Wilcoxon signed rank test.
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which signiﬁcantly lowered the endothelial cell survival rate
(Fig. 5c).
Collectively, these in vitro data support the notion that missing
self-induced NK cell activation has a deleterious impact on graft
vasculature.
MS triggers NK cell-mediated rejection in vivo. We next
investigated the impact of missing self-induced NK cell activation
in vivo in the context of transplantation. We adapted the het-
erotopic heart transplantation model as shown in Fig. 6a. Heart
grafts, harvested in wild-type C57B/L6 (controls) or ß2-
microglobulin KO mice, were transplanted to wild-type C57B/
L6 mice. As observed in the clinic, the mere absence of MHC I
molecules on the graft endothelium was insufﬁcient to promote
the development of histological lesions (group ß2-microglobulin
KO into C57B/L6, ß2→B6; Fig. 6b, d). However, the priming of
recipients’ NK cells induced by mild ischaemia/reperfusion
injuries resulted in the appearance of MVI, speciﬁcally in ß2-
microglobulin KO heart transplants (groups ß2-microglobulin
KO into C57B/L6+ ischaemia, ß2→B6+ isch vs. C57B/L6 into
C57B/L6+ ischaemia, B6→B6+ isch; Fig. 6b, d). Similar results
were obtained when the priming of NK cells was performed
with Poly (I:C), a surrogate for viral infection (Supplementary
Fig. 7B, C). Graft MVI in this model was similar to that observed
in MVI+DSA− patients: circulating CD45+ immune cells,
including Nkp46+ NK cells, were found to adhere to CD31+
turgid capillary ECs (Fig. 6c, d). The central role of NK cells in
this type of rejection was demonstrated by the complete dis-
appearance of lesions in ß2-microglobulin KO heart grafts
transplanted to recipients, whose NK cells were depleted by anti-
NK1.1 mAb (group ß2-microglobulin KO into C57B/L6+
ischaemia+ anti-NK1.1, ß2→B6+ isch+ αNK1.1; Supplemen-
tary Fig. 7A, Fig. 6b–d).
MS triggers mTORC1 signalling in NK cells. To gain insight
into the molecular mechanisms involved in missing self-induced
NK cell activation, puriﬁed human NK cells of healthy volunteers
were co-cultured with K562 cells, an MHC I-deﬁcient human
cell line.
Based on previous work from our group41,42, the analysis
focused on the mTOR pathway. The phosphorylation status of S6
ribosomal protein (S6RP) and protein kinase B (Akt), located
downstream from mTORC1 and mTORC2 complexes, respec-
tively, was longitudinally assessed in NK cells using imaging ﬂow
cytometry (Supplementary Fig. 8A, Fig. 7a). While isolated NK
cells showed only a modest increase in p-S6RP, the mTORC1
pathway was strongly activated in NK cells that had formed
doublets with K562 targets (Fig. 7a, b). By contrast, no signiﬁcant
change was observed regarding the phosphorylation status of Akt
in NK cells, which suggests that mTORC2 does not play a role in
missing self-induced NK cell activation (Fig. 7a, c).
Analysis of graft biopsies from patients with missing self-
induced NK cell-mediated rejection conﬁrmed that the mTORC1
pathway was activated in NK cells adherent to graft micro-
vasculature (Fig. 7d).
mTOR inhibitor prevents MS-induced NK-mediated rejection.
Based on the molecular data presented above and data from the
literature43–45, we hypothesised that mTOR inhibitors might have
potent therapeutic effects against missing self-induced NK-
mediated rejection.
First, the ability of the mTOR inhibitor rapamycin to block the
mTORC1 pathway and suppress missing self-induced cytotoxicity
of human NK cells was evaluated ex vivo. NK cells were puriﬁed
from the circulation of 24 patients before and 1 month after
introduction of the mTOR inhibitor and the level of phosphor-
ylation of S6 ribosomal protein (S6RP, which is located down-
stream mTORC1) was measured by ﬂow cytometry. Exposure to
the drug in vivo not only decreased the baseline level of
phosphorylation of S6RP in NK cells, but also drastically reduced
their response to the stimulation by IL-15 (Fig. 8a, Supplementary
Fig. 4C). As expected from the above, adjunction of mTOR
inhibitor to co-cultures of K562 cells and human NK cells
reduced missing self-induced cytotoxicity (Fig. 8b).
To further validate the therapeutic potential of mTOR inhibitor
in missing self-induced NK-mediated rejection, the effects of an
mTOR inhibitor and a calcineurin inhibitor were compared in the
in vivo mouse model (Fig. 8c). In line with our hypothesis,
calcineurin-inhibitor-treated animals developed the same MVI as
untreated controls, but recipient mice treated with an mTOR
inhibitor showed signiﬁcantly less endothelial turgidity and
inﬂammatory effectors in heart graft capillaries (Fig. 8d–f).
Our data therefore validate the idea that therapeutic mTOR
inhibition may protect transplant recipients against missing self-
induced NK-mediated rejection.
Discussion
In the present study, we demonstrate that the allogeneic nature of
graft ECs sometimes creates “missing self”, a situation that can be
sensed by primed NK cells in the recipient’s circulation. Missing
self-induced NK cell activation promotes the development of
graft MVI that has the exact same detrimental impact on organ
survival as non-complement activating anti-HLA DSA, the pri-
mary cause of late transplant loss6–8. However, while there is
currently no efﬁcient therapy against antibody-mediated chronic
vascular rejection, our study established that missing self-induced
NK cell activation is dependent upon the mTORC1 pathway and
can be blocked by mTOR inhibitors, a commercially available
class of immunosuppressive drugs46. Preclinical studies, using
experimental murine models, suggested that therapeutic
mTORC1 inhibition can prevent the development of histological
lesions.
We believe that this data can have several levels of signiﬁcance.
Firstly, clinicians in charge of transplant patients are frequently
confronted with MVI lesions on graft biopsy. As an illustration,
the prevalence of MVI lesions was estimated to be as high as
13.8% in our cohort of renal transplant patients, although we do
not perform HLA incompatible transplantations (i.e. transplan-
tation in the presence of preformed anti-HLA DSA) in our centre.
Until now, MVI lesions have been considered as the hallmark of
AMR. Our data instead suggest that in half of the cases, MVI is
the result of an unrecognised type of rejection due to the “direct”
activation of recipient’s NK cells by missing self.
An intriguing question is why previous large clinical studies
have failed to detect the detrimental impact of genetically pre-
dicted KIR-ligand incompatibility on renal allograft survival47,48.
Our results clearly show that genetically predicted missing self is
not a sufﬁcient condition to develop NK cell-mediated rejection.
Firstly, patients with similar genetic proﬁles exhibit high inter-
individual heterogeneity in the size of the NK cell population able
to sense the missing self. Secondly, even among patients (and
mice) with sufﬁcient NK cells able to sense the missing self, only
those whose NK cells were previously primed (by ischaemia/
reperfusion injuries or a viral infection) went on to develop MVI
lesions. Finally, another layer of complexity may arise from the
fact that NK cells have also been shown to regulate the alloim-
mune response through the killing of donor antigen-presenting
cells49–51.
Although missing self-induced and non-complement-activating
anti-HLA AMRs have the same detrimental impact on graft
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survival, it is crucially important to differentiate these two con-
ditions. Patients with missing self-induced rejection will not
respond to the costly and tedious treatment of AMR, which
associates plasmapheresis with high-dose intravenous immu-
noglobulins6. The mixture of authentic cases of AMR with
previously unrecognised cases of missing self-induced rejection
might explain the high heterogeneity in response to treatment6,15.
Furthermore, our results demonstrate that therapeutic mTORC1
inhibition efﬁciently prevents the development of histological
lesions due to missing self-induced NK cell activation in a murine
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experimental model of transplantation. Of note, on the basis of
conﬂicting clinical reports suggesting that mTOR inhibitors might
be less potent in preventing DSA generation52–55. transplanted
patients with graft MVI (and wrongly diagnosed with AMR) are
often switched from an mTOR inhibitor-based to calcineurin-
inhibitor (CNI)-based maintenance regimen. This is probably
detrimental to graft survival because our data show that CNI have
no impact on missing self-induced rejections. A note of caution
should, however, be sounded in the case of renal transplantation.
NK cell-induced microvascular lesions in the glomeruli may
trigger signiﬁcant stress on podocytes. These key cellular players of
the ﬁltration barrier are known to adapt to stress through mTOR
pathways56,57 and it is therefore possible that introduction of
mTOR inhibitors late in the course of the disease (i.e. in the
presence of proteinuria and/or chronic glomerular lesions on the
biopsy) could be ill-tolerated in these patients.
Beyond its clinical impact, our work is also of interest for basic
immunologists. Until very recently, rejection of allografts was
thought to be strictly dependent on the recipient’s adaptive
immune system. The consensus sequence described in textbooks
starts with the recognition of donor-speciﬁc HLA molecules by the
recipient’s T lymphocytes through direct or indirect pathways58,59.
Direct allorecognition of donor-speciﬁc HLA molecules as intact
complexes on the surface of passenger leucocytes activates up to
10% of a recipient’s T cells, which triggers acute cellular rejection.
By contrast, the “indirect” recognition of allogeneic peptides,
presented within MHC-II molecules on the surface of the reci-
pient’s APCs, activates much fewer CD4+ T cells, but these are
critically important for the generation of alloantibodies60. In this
prevalent model, innate immune cells in general (and NK cells in
particular) are merely considered as downstream effectors that
participate in the destruction of the graft only upon recruitment
by the adaptive immune system31,61,62.
Our present work challenges this vision and coincides with the
concept of innate allorecognition63, which proposes that the
innate immune system alone can promote rejection of trans-
planted organs. The ﬁrst experimental evidence supporting this
notion came in the 1960s from the observation that bone marrow
grafted from parental strains of mice to F1 hybrids between the
parental strain and a second strain was rejected, a process referred
to as “hybrid resistance”64. Hybrid resistance was later linked to
the ability of NK cells to react to missing self65, but for years this
process was not thought to be involved in solid tissue rejection
because Snell’s third “law of transplantation” stated that “skin
grafts from either inbred parent strain to the F1 hybrid suc-
ceed”66, and MHC homozygous embryonic stem cell-derived
teratomas form and persist in MHC heterozygous mice67. We
believe that the lack of impact of missing self-induced NK cell
activation in these two models is due to the fact that in both cases
the graft vasculature comes from the recipient13 and therefore has
a “normal” expression of self-MHC. Our hypothesis is consistent
with the seminal work by Uehara et al.68 (who reported that
missing self-induced NK cell activation leads to the development
of chronic allograft vasculopathy with no accompanying inter-
stitial inﬂammation in parental cardiac grafts transplanted to F1
hybrid recipients), and the fact that histological lesions were
limited to the graft vasculature in both the patient biopsies and
the murine experimental model in our own study.
Importantly, NK cells might not be the only innate immune
effectors capable of innate allorecognition, as ~1/3 of MVI+
DSA− patients in our cohort had no genetically predicted
missing self, suggesting that other innate immune effectors are
able to induce antibody-independent graft MVI. Recent data from
Fadi Lakkis’s group identiﬁes the recipient’s monocytes as
probable culprits. Monocytes are indeed able to distinguish
between self and allogeneic non-self through the expression of
CD47, a surface receptor able to sense SIRPα polymorphism in
the donor69. In accordance with this theory, it has been reported
that depleting macrophages from recipients of parental to F1
cardiac transplants did reduce the formation of chronic allograft
vasculopathy in an murine experimental model70.
In conclusion, this study identiﬁes a type of chronic rejection,
whose pathophysiology is independent of the recipient’s adaptive
immune system. Missing self-induced NK cell-mediated chronic
vascular rejection is as prevalent as AMR and has the same det-
rimental impact on organ survival. However, while there is cur-
rently no efﬁcient therapy against chronic AMR, commercially
available mTOR inhibitors have shown promising efﬁcacy in
preventing the development of histological lesions in a preclinical
murine model of missing self-induced NK cell-mediated chronic
vascular rejection.
Methods
Human studies. The study was carried out in accordance with French legislation
on biomedical research and the Declaration of Helsinki. All patients gave informed
consent for the utilisation of clinical data [Donneés Informatiques Valideés en
Transplantation (DIVAT)] and biological samples for research purpose. For
DIVAT, a declaration was made to the CCTIRS (Comité consultatif sur le Trai-
tement de l’Information en matière de Recherche dans le domaine de la Santé) and
the CNIL (Commission nationale de l’Informatique et des Libertés). For the bio-
collection, an authorisation (No. of biocollection: AC- 2011-1375 and #AC-2016-
2706) was obtained from the French Ministry of Higher Education and Research
(direction générale pour la recherche et l’innovation, cellule bioéthique).
The computer database (DIAMIC) of the Lyon University Hospital pathology
department was used to screen all kidney-allograft biopsies (2024 biopsies in 938
patients) performed between 1 September 2004 and 1 September 2012 for
microvascular inﬂammation (MVI+). The biopsies of the 143 patients were
systematically reviewed by the same trained pathologist (M. Rabeyrin), who graded
the lesions according to the Banff 2011 classiﬁcation. Fourteen patients, whose
biopsy analysis did not conﬁrm the presence of MVI lesions (Banff g+ ptc score <
2) were excluded. Computer-assisted analyses were conducted to quantify T cells, B
cells, granulocytes, macrophages and NK cells in the patient biopsies.
Clinical data of the 129 patients enrolled in the study obtained with DIVAT
were crosschecked with the CRISTAL database [Cristal: http://www.sipg.sante.fr/
portail/]. The patient characteristics are summarised in Supplementary Table 1.
Serum samples banked at the time of biopsy were screened for the presence of
anti-HLA DSA, and, if positive, for the ability of these anti-HLA DSA to bind the
complement fraction C3d. These centralised analyses were performed in a blinded
fashion with single-antigen ﬂow bead assays according to the manufacturer’s
instructions (Immucor, Norcross, GA, USA). If negative, all the serum samples
collected during the follow-up of the patients were checked to conﬁrm this
negativity. To rule out the presence of non-HLA donor-speciﬁc antibodies,
negative sera were tested in endothelial ﬂow cross-match assay.
The steps leading to the distribution of patients into the ﬁrst three groups of
patients (MVI+DSA+C3d+, n= 40; MVI+DSA+C3d−, n= 30; and MVI+
DSA−, n= 53) are summarised in Fig. 1a.
Fig. 6Missing self triggers NK cell-mediated rejection in vivo. a Schematic representation of the murine experimental models. Wild-type C57BL/6 (B6) mice
were transplanted with either a C57BL/6 or a β2-microglobulin KO heart (β2). In some cases, the heart was subjected to 3 h of cold ischaemia before
transplantation (+Isch). Some recipients were treated with anti-NK depleting mAb (+αNK1.1). Heart grafts were harvested 60 days after transplantation for
histological analysis. b Representative ﬁndings of H&E stain are shown for the four experimental groups (two independent experiments): from top to bottom
β2→B6 (n= 4); β2→B6+ Isch (n= 8); β2→B6+ Isch+ αNK1.1 (n= 5); and B6→B6+ Isch (n= 8). Scale bars: 100 μm. c Immunohistochemistry was
performed to evaluate the morphology of the microvasculature (CD31), the immune cell inﬁltration (CD45), and the NK cell inﬁltration (Nkp46).
Representative ﬁndings are shown for the four experimental groups (two independent experiments). Scale bars: 100 μm. d A trained pathologist blindly
graded the intensity of each elementary lesion on a semi-quantitative scale (score 0–3). Mean ± standard deviation. *p < 0.05; **p < 0.01; one-way ANOVA.
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A control group, without MVI on graft biopsy, nor circulating DSA (MVI−
DSA−, n= 75), but matched for the main clinical characteristics of the MVI+
DSA− patients, was established from the pool of 938 patients.
Clinical pathology. Kidney graft biopsies were performed systematically as part of
the routine follow-up procedure at 3 months and 1-year post-transplantation, or if
rejection was suspected at the other time points.
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Fig. 7 Missing self-induced NK cell activation is mTORC1-dependent. a–c Puriﬁed NK cells from a healthy donor were co-cultured with HLA-deﬁcient K562
cells. An imaging ﬂow cytometer was used at indicated time points to detect the phosphorylated form of S6 ribosomal protein (S6RP, downstream mTORC1)
and of protein kinase B (Akt, downstream mTORC2), in isolated NK cells and NK cells that form doublets with K562 target cells. a Representative images of
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Renal specimens were ﬁxed in acetic acid–formol–absolute alcohol, and
parafﬁn-embedded sections were stained by routine methods. C4d staining was
performed by indirect immunoﬂuorescence on frozen sections using an anti-
human C4d complement-rabbit clonal antibody (clone A24-T, produced by DB
Biotech, Kosice, Slovak Republic).
The renal pathologist (M. Rabeyrin) who reviewed the biopsy specimens was
blinded to clinical and immunological data.
For CAGI, double stainings with anti-CD34 (endothelial cells) and respectively
one antibody among anti-CD3 (T cells), anti-CD20 (B cells), anti-CD66b
(granulocytes), anti-CD68 (macrophages) and anti-CD56 (NK cells) were
performed by immunochemistry on parafﬁn-embedded sections using an anti-
human CD34 (clone QBEnd10, 1/200, Dako, Les Ulis, France) and respectively
anti-human CD3 (clone SK7, 1/150, Becton Dickinson, Le Pont de Claix, France),
anti-human CD20 (Clone L26, 1/400, Dako), anti CD66b (clone G10F5, 1/300,
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Becton Dickinson), anti-human CD68 (clone PGM1, 1/100, Dako) and anti-human
CD56 (clone CD564, 1/10, produced by Novocastra and distributed by Leica
Microsystemes SAS, Nanterre, France). Of note, CD56 staining, although extremely
sensitive (94%) is not fully speciﬁc for NK cells. About 3/4 of CD56+ cells are NK
(Nkp46+). Most CD56+Nkp46− cells are either NKT or CD8+ T cells.
Computerised quantitative analyses were conducted to quantify the density of
each immune cell type in the microcirculation and tubulointerstitial compartment
of the renal allograft.
For heart graft biopsies, phosphorylated-S6RP staining was performed by
immunohistochemistry on parafﬁn-embedded sections using an anti-human p-
S6RP(Ser240/244) antibody (clone D68F8, produced by Cell Signaling Technology,
Leiden, The Netherlands) according to Tible et al.71.
Detection of anti-HLA antibodies. Serum samples, banked at the time of biopsy
from patients with signiﬁcant MVI, were diluted ﬁvefold in washing buffer and
tested for the presence of donor-speciﬁc anti-HLA antibodies using Screening Flow
Beads (LifeScreen, Class I and Class II ID ®, Lifecodes, Immucor) and Single
Antigen Flow Beads (LSA class I and class II®, Lifecodes, Immucor) in the case of
positivity or a questionable result of the screening test. To rule out a false-negative
result due to interference with complement proteins, all sera positive in Screening
Flow Beads but without identiﬁed DSA in Single Antigen Flow Beads were retested
after a pre-treatment with EDTA.
All the sera of MVI+DSA− and MVI−DSA− patients collected before the
biopsy were also checked, and patients with circulating donor-speciﬁc anti-HLA
antibodies detected at any time point were excluded.
All the analyses were performed in a blinded fashion by the same trained
immunobiologist (V.D.) at the Etablissement Français du Sang, Lyon, France.
Detection of non-HLA antibodies. Sera of patients were screened for the presence
of anti-AT1R and anti-MIC antibodies using a multiplex solid-phase assay
(Immucor).
To detect non-HLA anti-endothelial cell antibodies, we used a ﬂow cross-match
technique. Brieﬂy, target ECs were HLA-matched to avoid false-positive tests due
to HLA binding (for sera containing anti-HLA antibodies that were not speciﬁc to
kidney donor). Conﬂuent endothelial cell monolayers were starved overnight in
endothelial cell basal medium supplemented with 2% fetal bovine serum (FBS)
without growth factors and incubated with recombinant human tumour necrosis
factor α (TNF-α) (100 U/mL; Peprotech) for 48 h. ECs were then dissociated with
trypsin, and 1–2 × 105 ECs were incubated for 30 min at room temperature with
25 μL of serum ¼ diluted in PBS 1× FBS 1%. Reactivity of patient’s sera for ECs was
revealed by incubation with an FITC-conjugated F(ab′)2 anti-human IgG (clone
30242; Bio rad, Hercule, CA, USA) for 20 min at 4 °C. The ﬂuorescence level was
expressed as mean ﬂuorescence intensity. A serum containing an anti-HLA class I
antibody directed against HLA typing of the endothelial cell lines was used as
positive control. Negative controls were performed using a pool of human AB sera
from healthy male donors.
Results are expressed as a ratio of the MFI obtained with patients’ sera to that
obtained with the negative control. A value of the ratio greater than 1.5 was
considered as positive.
HLA and KIR genotyping. Donor and recipient HLA typing were performed by
PCR-SSO reverse (One Lambda, Canoga Park, CA, USA). HLA-C1 and C2 groups
were determined for the donors and recipients considering the HLA C typing
obtained by PCR-SSO reverse (One Lambda). The presence or absence of Bw4
motif was determined for the donors and recipients, considering the HLA A and B
typing obtained by PCR-SSO reverse (One Lambda).
Recipients were genotyped for the 14 KIR genes (2DL1, 2DL2, 2DL3, 2DL4,
2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1) and two
pseudogenes (2DP1, 3DP1) by PCR-SSO reverse (KIR SSO Genotyping Test, One
Lambda and Lifecodes KIR Genotyping, Immucor).
Genetic prediction of missing self. 2DL1, 2DL2, 2DL3, 3DL1, 3DL2 inhibitory
KIRs educated NK cells only when the recipient expressed their respective HLA
class I ligand: KIR2DL1/C2; KIR2DL2/C1; KIR2DL3/C1; KIR3DL1/Bw4 and
KIR3DL2/A*03, *11.
Genetic prediction of missing self was deﬁned as the lack of expression by the
graft of the type of HLA class I molecule able to bind to an educating inhibitory
KIR of the recipient (Fig. 2a).
Cell preparation and cultures. The human erythroleukemia cell line K562, which
lacks expression of any MHC molecules, was kindly provided by I. Doxiadis,
University of Leiden, Netherlands. It was cultured in RPMI-1640 (ThermoFisher
Scientiﬁc, Courtaboeuf, France) complemented with foetal bovine serum (FBS)
10% (Dutscher, Brumath, France), L-glutamine 2 mM (ThermoFisher Scientiﬁc),
penicillin 100 U/mL, streptomycin 100 μM and HEPES 25 mM (ThermoFisher
Scientiﬁc) (hereafter referred to as “complete RPMI”).
Primary human arterial ECs were isolated from organ donors (agreement
PFS08-017 from the Agence de la Biomédecine, https://www.agence-biomedecine.
fr) and prospectively stored in the DIVAT biobank (no. of biocollection #02G55).
They were cultured in endothelial cell growth medium 2 (Promocell, Heidelberg,
Germany) in ﬂasks coated with ﬁbronectin (Promocell) or gelatine 1% (Sigma,
Saint Quentin-Fallavier, France) and used between passages 2 and 7. For some
experiments, ECs were activated with recombinant human TNF-α (100 U/mL,
Peprotech) for 48 h.
PBMCs were isolated from the blood of healthy volunteers by Ficoll gradient
centrifugation (Eurobio, Courtaboeuf, France). PBMCs were cultured overnight at
37 °C in 5% CO2 in complete RPMI supplemented with recombinant human IL-2
(R&Dsystems, Minneapolis, MN, USA) or were maintained at 4 °C in complete
RPMI. NK cells were puriﬁed (>90%) from PBMCs by negative selection with
magnetic enrichment kits (Stemcell, Grenoble, France).
Flow cytometry. For NK cell count, 200 μL of blood was incubated with anti-CD45
(clone 30-F11, 1/400; BioLegend, London, UK), anti-CD3 (clone SK7, 1/10; BD
biosciences, Le Pont de Claix, France) and anti-CD56 (clone NCAM16.2, 1/10; BD
biosciences) antibodies. The samples were then incubated with a Lysing Solution
(BD biosciences) to eliminate the red blood cells. Lymphocyte count was per-
formed with ABX Pentra 60C+ (Horiba, Irvine, CA, USA).
For KIR phenotyping, single-cell suspensions of human PBMCs were incubated
with a ﬁxable viability dye (ThermoFisher Scientiﬁc) for 20 min at 4 °C. After
washing, the cells were incubated ﬁrst with anti-CD19 (clone HIB19, 1/10, BD
biosciences), anti-CD14 (clone M5E2, 1/10; BD biosciences), anti-CD3 (clone SK7,
1/10; BD biosciences), anti-CD56 (clone NCAM16.2, 1/10; BD biosciences), anti-
KIR3DL1 (clone DX9, 1/25; BD Biosciences), anti-KIR2DL1/S5 (clone 143211, 1/
10; R&Dsystems), and anti-KIR2DL3 (clone 180701,1/10; R&Dsystems) antibodies
for 15 min at room temperature and then with anti-KIR2DL1/S1 (clone EB6B, 1/
25; Beckman Coulter, Villepinte, France), anti-KIR2DL2-3/S2 (clone GL183, 1/25;
Beckman Coulter), and anti-KIR3DL1-2 (clone REA168, 1/10; Miltenyi Biotec,
Bergisch Gladbach, Germany) antibodies for an additional 15 min. The cells were
then ﬁxed with paraformaldehyde 2% (ThermoFisher Scientiﬁc) and the sample
was stored at 4 °C until analysis.
All sample acquisitions were made on a LSR FORTESSA or a FACScanto II®
ﬂow cytometer (BD biosciences) and analyses were performed with FlowJo
software version 10.0.8r1 (Tree Star Inc, Ashland, OR, USA).
Imaging ﬂow cytometry. Puriﬁed human NK cells (105) were mixed with K562
cells at a ratio of 1:1 in V-bottomed 96-well plates, centrifuged at 100g for 1 min,
and incubated 30 min, 1 h, 2 h or 3 h at 37 °C at 5% CO2. Negative controls were
NK cells cultured alone and positive controls were NK cells cultured with IL-15
(100 ng/mL; Peprotech).
At indicated time points, the cells were harvested, stained with a ﬁxable viability
dye (ThermoFisher Scientiﬁc) and then surface-stained with anti-CD3 (clone SK7,
Fig. 8mTOR inhibition prevents missing self-induced NK cell-mediated rejection in vivo. a PBMCs from 24 patients were collected before and 1 month after
injection of an mTOR inhibitor and p-S6RP was quantiﬁed in NK cells stimulated (IL-15+) or not with IL-15 (IL-15−). Representative ﬂow cytometry proﬁles
are shown (left panel). The relative increase of p-S6RP signal in NK cells after stimulation with IL-15 is shown (right panel). Each circle is a patient. Results
obtained before (open circles) and after mTOR inhibitor introduction (black circles) were compared. ****p < 0.0001; Wilcoxon signed rank test. b Puriﬁed
NK cells from eight healthy volunteers were co-cultured with K562 cells at different effector-to-target ratios (E:T) for 6 h in presence (mTORinh+) or not
(mTORinh−) of an mTOR inhibitor. Viability of target cells was compared. *p < 0.05, **p < 0.01, ***p < 0.001; Mann–Whitney test. c–f. Wild-type C57BL/6
mice were transplanted with β2-microglobulin KO hearts subjected to 3 h of cold ischaemia. Recipient mice were treated with vehicle (control, Ctrl): a
calcineurin inhibitor (CNI) or an mTOR inhibitor (mTORinh). Heart grafts were harvested 60 days after transplantation for histological analysis. Two
independent experiments. c Graphical summary of the model. d Representative ﬁndings of H&E stain are shown for the three experimental groups: from
top to bottom Ctrl (n= 8); CNI (n= 5); mTORinh (n= 7). Scale bars: 100 μm. e Immunohistochemistry was performed to evaluate the morphology of the
microvasculature (CD31), the immune cell inﬁltration (CD45), and the NK cell inﬁltration (Nkp46). Representative ﬁndings are shown for the three
experimental groups. Scale bars: 100 μm. f A trained pathologist blindly graded the intensity of each elementary lesion on a semi-quantitative scale (score
0–3). Mean ± standard deviation. ns:p≥ 0.05; *p < 0.05; **p < 0.01; ****p < 0.0001; one-way ANOVA. Source data are provided as a Source Data ﬁle.
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1/10; BD Biosciences), and anti-CD56 (clone NCAM16.2, 1/10; BD Biosciences)
antibodies. The cells were subsequently ﬁxed, permeabilised (Lyseﬁx/PermIII®
ﬁxation/permeabilisation kit; BD Biosciences) and stained with anti-phospho-S6
ribosomal protein Ser 235/236 (clone D57.2.2E, 1/50; Cell Signaling Technology,
Leiden, The Netherlands) or anti-PAkt S473 (clone M89-61, 1/40; BD Biosciences)
antibodies.
Sample acquisitions were made on an ImageStream X Mark II (Amnis-EMD
Millipore, Darmstadt, Germany) with ×40 magniﬁcation and analysed with IDEAS
software (v6.0).
NK cell activation in vitro. For analysis of missing self-NK activation, PBMCs
were cultured overnight in RPMI supplemented with 500 IU/mL of recombinant
human IL-2 (R&Dsystems). Puriﬁed NK cells (105 cells) were then mixed with ECs
at a ratio of 1:1 in ﬂat-bottomed 96-well plates, centrifuged at 100g for 1 min, and
incubated at 37 °C at 5% CO2. Anti-CD107a-FITC (clone H4A3, 5 µL; Thermo-
Fisher Scientiﬁc) was added prior the start of the assay. One hour after the
beginning of the co-culture, Golgi Stop (BD Biosciences) was added to each well.
After 4 h of co-culture, the cells were harvested and surface-stained with
appropriate antibody combinations to identify KIR subsets. The cells were
subsequently ﬁxed and permeabilised (Cytoﬁx/Cytoperm ﬁxation/permeabilisation
kit; BD Biosciences), stained with anti-MIP-1ß-V450 (clone D21-1351, 1/40; BD
biosciences) antibodies and analysed by ﬂow cytometry.
For analysis of IL15-induced mTORC1 activation in NK cells, PBMCs of 24
patients diagnosed with breast cancer were collected before and one month after the
introduction of a mTOR inhibitor (everolimus). PBMCs were cultured for 1 h in
complete RPMI. When indicated, 100 ng/mL of IL-15 was added to the cultures. After
1 h, the cells were harvested and surface-stained with appropriate antibody
combinations: anti-CD7 (clone 8H8.1, 1/50; Beckman Coulter) and anti-CD3 (clone
SK7, 1/10; BD Biosciences). The cells were subsequently ﬁxed and permeabilised
(Cytoﬁx/Cytoperm ﬁxation/permeabilisation kit; BD Biosciences), stained with anti-
phospho-S6 ribosomal protein Ser 235/236 (clone D57.2.2E, 1/50; Cell Signaling
Technology, Leiden, The Netherlands) antibody and analysed by ﬂow cytometry.
In vitro cytotoxicity assays. For analysis of endothelial cell viability, PBMCs were
cultured overnight in RPMI supplemented with 60 IU/mL of recombinant human IL-
2 (R&D Systems). In each culture well, 104 human primary ECs (either Bw4− or
Bw4+) were seeded. After 24 h, 105 puriﬁed NK cells from KIR3DL1+ or KIR3DL1−
donors were added to the culture. When indicated, 0.5 µg of anti-KIR3LD1 blocking
monoclonal antibody (clone DX9; BD Biosciences) or an isotype control was added to
the cultures.
Endothelial cell viability was monitored every 5 min for 10 h by electrical
impedance measurement with an xCELLigence RTCA SP instrument (ACEA
Biosciences, San Diego, CA, USA). The cell indices (CI) were normalised to the
reference value (measured just prior to adding NK cells to the culture). Endothelial
cell viability in the experimental well was normalised over the control well.
For analysis of K562 viability, PBMCs collected from eight healthy volunteers
were co-cultured with 2500 K562 cells transfected with NanoLuc® luciferase at
different effector-to-target ratios. When indicated, 25 nM of mTOR inhibitor
(rapamycin) was added to the cultures. After 6 h of co-culture, 50 µL of supernatant
of each well was collected and Nano-Glo® Luciferase Substrate (Promega, Madison,
WI, USA) was added. K562 cell viability was assessed by measurement of
luminescence for each well with an Inﬁnite® 200 PRO instrument (TECAN,
Männedorf, Switzerland).
Mice. Wild-type C57BL/6 (H-2b) mice aged 8–15 weeks were purchased from
Charles River Laboratories (Saint-Germain sur l’Arbresle, France).
C57BL/6 mice in which ß2-microglobulin gene has been deleted (hereafter
referred as ß2-microglobulin KO) lack MHC class I protein expression on the cell
surface. These mice were kindly provided by Laurent Genestier (CRCL, UMR
INSERM 1042 CNRS 5286 Centre Léon Bérard).
All mice were maintained in germ-free conditions in our animal facility: Plateau
de Biologie Expérimentale de la Souris (http://www.sfr-biosciences.fr/plateformes/
animal-sciences/AniRA-PBES; Lyon, France).
All studies and procedures were performed in accordance with EU guidelines
and were approved by the local ethical committee for animal research (CECCAPP
Lyon, registered by the French National Ethics Committee of Animal
Experimentation under No.15, http://www.sfr-biosciences.fr/ethique/
experimentation-animale/ceccapp).
NK cell depletion in vivo. Where indicated, in the heart transplant model, mice
were given intraperitoneally 100 µg of anti-NK1.1 monoclonal antibody (clone
PB136; BioXcell, West Lebanon, NH, USA) twice a week from day −7 to the end of
the experiment. NK cell depletion was veriﬁed by ﬂow cytometry by quantifying
the number of circulating Nkp46+ cells.
Heart transplantation model. Cardiac allografts were transplanted into sub-
cutaneous space of the right neck. Anastomoses were performed by connecting the
ascending aorta of the graft end-to-end with the recipient’s common carotid artery
and by pulling the main pulmonary artery with the external jugular vein as
described in ref. 13
Where indicated, mice were injected intraperitoneally with 100 µg of poly(I:C)
(polyinosinic–polycytidylic acid; Invivogen, Toulouse, France) at day 4.
When indicated, the heart graft was kept at 4 °C for 3 h before transplantation
to induce ischaemia/reperfusion injuries.
Heart transplants were harvested 60 days after transplantation, ﬁxed in 4%
buffered formalin for 24 h and embedded in parafﬁn for haematoxylin and eosin
stain and immunohistochemistry. The following primary antibodies were used:
anti-mouse CD31 (clone SZ31; 1/50; Dianova, Hamburg, Germany), anti-mouse
CD45 (clone 30-F11; 1/40; BD Biosciences), and anti-Nkp46 (kind gift from Innate
Pharma, Marseille, France) to stain, respectively, the ECs, the hematopoietic cells
and the NK cells. The sections were revealed by Vectastain ABC HRP Kit (Vector,
Peterborough, UK). The amount of labelled cells was semi-quantitatively assessed
as follows: 0 normal; 1+ minimal or rare foci; 2+ moderate or several foci; 3+
marked or multifocal or diffuse.
When indicated, mice were given intraperitoneal injections of a calcineurin
inhibitor (cyclosporin, Sandimmum; Novartis, Rueil-Malmaison, France) 20 mg/
kg/day or an mTOR inhibitor (rapamycin; Bio Basic, Amherst, NY, USA) 3 mg/kg/
day from day −7 to the end of the experiment.
Statistical analyses. For each dataset, mean ± standard deviation was calculated.
For graphical presentation of the same data sets, box plots were generated using
Prism software (Version 6.01; GraphPad Software Inc., La Jolla, CA), which pre-
sents the entire dataset distribution. The centre line in the boxes shows the med-
ians; the box limits indicate the 25th and 75th percentiles; the whiskers indicate the
10th and 90th percentiles.
Differences between the groups were evaluated by the Mann–Whitney test,
Fisher’s exact test, unpaired t-test, one-way ANOVA followed by a Tukey’s post
hoc test, or by two-way ANOVA followed by a Šidák’s post hoc test, according to
the size of the groups and the distribution of the variable. All the tests used were
two-sided. The test used for comparison is indicated in the ﬁgure legends.
Renal graft survivals were compared using the log-rank test.
Quadratic discriminant analysis was conducted on the CAGI dataset using the
JMP software (Version 14; SAS Institute Inc., Cary, NC, USA).
The differences between the groups were considered statistically signiﬁcant for
p < 0.05 and are reported with asterisks (*p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the ﬁndings of this study are available in the
article and its Supplementary Information Files, or on request from the corresponding
author. The source data underlying Fig. 3A, Fig. 4C, D, Fig. 7B, C, Fig. 8B,
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source data ﬁle.
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